Insight Genetics Awarded New National Cancer Institute Contract To Identify Resistance Mutations In Lung Cancer Patients
Published: Jan 08, 2014
NASHVILLE, Tenn.--(BUSINESS WIRE)--Insight Genetics, Inc. today announced it has received a new $1.5 million Phase II Small Business Innovation Research (SBIR) contract from the National Cancer Institute (NCI). A continuation of a Phase I contract NCI awarded to Insight Genetics in 2011, the new contract will allow the company to continue its development of Insight ALK Resistance™, a diagnostic test that helps clinicians monitor their non-small cell lung cancer (NSCLC) patients for resistance to their prescribed cancer therapy.
Help employers find you! Check out all the jobs and post your resume.